Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933

By Lee Sylvia M.   Moon James   Redman Bruce G.   Chidiac Tarek   Flaherty Lawrence E.   Zha Yuanyuan   Othus Megan   Ribas Antoni   Sondak Vernon K.   Gajewski Thomas F.   Margolin Kim A.  

Cancer, Vol. 121, Iss. 3, 2015-02 ,pp. : 432-440

Blackwell Publishing

Access to resources Recommend Favorite

AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo

By Torres Mylin   Raju Uma   Molkentine David   Riesterer Oliver   Milas Luka   Ang K.  

Investigational New Drugs, Vol. 29, Iss. 4, 2011-08 ,pp. : 554-561

Springer Publishing Company

Access to resources Recommend Favorite

Gamma-Secretase as a Pharmacological Target in Alzheimer Disease Research: When, Why and How?

By  

Current Pharmaceutical Design, Vol. 12, Iss. 33, 2006-11 ,pp. : 4313-4335

Bentham Science Publishers

Access to resources Recommend Favorite

Formation and Anti-Tumor Activity of Uncommon In Vitro and In Vivo Metabolites of CPI-613, a Novel Anti-Tumor Compound That Selectively Alters Tumor Energy Metabolism

By  

Drug Metabolism Letters, Vol. 5, Iss. 3, 2011-08 ,pp. : 163-182

Bentham Science Publishers

Access to resources Recommend Favorite

Metabolism of Loratadine and Further Characterization of Its In Vitro Metabolites

By  

Drug Metabolism Letters, Vol. 3, Iss. 3, 2009-08 ,pp. : 162-170

Bentham Science Publishers

Access to resources Recommend Favorite